Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency (IGHD)

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00630487
First received: February 28, 2008
Last updated: February 26, 2013
Last verified: February 2013

February 28, 2008
February 26, 2013
May 2008
October 2008   (final data collection date for primary outcome measure)
Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI) [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.
The change of visceral fat mass assessed by magnetic resonance imaging scanning (MRI) after 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00630487 on ClinicalTrials.gov Archive Site
  • Change in Visceral Fat Mass in Subgroups [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
    Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).
  • Change From Baseline in Anthropometric Parameters (Height) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Anthropometric Parameters (Weight) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Anthropometric Parameters (Waist Circumference) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT]) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).
  • Change From Baseline in Blood Pressure [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.
  • Change From Baseline in Heart Rate [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.
  • Change in Executive Function and Memory in Subgroups [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.
  • Change From Baseline in Safety Laboratory Assessments [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: Yes ]
    Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.
  • Change From Baseline in Homeostasis Model Assessment (HOMA)-Index [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.
  • Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.
  • Change From Baseline in Short Form (36) Health Survey (SF36) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.
  • Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.
  • Change From Baseline in Cardiovascular Risk Factors [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
    Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)
  • Change in visceral fat mass in subgroups Change in cardiovascular risk factors (HDL, LDL, triglycerides) from baseline to week 52 and 78. [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in anthropometric parameters: height, weight, waist circumference after 52 and 78 weeks. [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change in alertness and memory from baseline to week 52 and additionally to week 78 [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to week 52 and 78 in vital signs (BP, HR). [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change in executive function and memory in subgroups [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to week 52 and 78 in safety laboratory assessments [ Time Frame: 78 weeks ] [ Designated as safety issue: Yes ]
  • Change in HOMA-Index from baseline to week 52 and additionally to week 78 [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Change in quality of life from baseline to week 52 and additionally to week 78 [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Incidence and number of adverse events [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency
Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)

The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass.

The study was terminated on 15-Dec-2008 due to poor recruitment. Although 9 Patients were enrolled, no patient was randomized nor treated with somatropin. No safety reasons contributed to the termination.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Growth Hormone Deficiency
  • Drug: Placebo
    Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
  • Drug: Somatropin
    Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Verum
    Intervention: Drug: Somatropin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
9
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females between 18 and 65 years of age
  • Isolated growth hormone deficiency

Exclusion Criteria:

  • Isolated growth hormone deficiency by childhood onset
  • Diabetes mellitus type 1 or 2
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00630487
A6281282
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP